Mumps virus-specific antibody titers from pre-vaccine era sera: Comparison of the plaque reduction neutralization assay and enzyme immunoassays

Journal of Clinical Microbiology

Volumn 43, Issue 9, 2005, Pages 4847-4851

  Mauldin, Jeremy ^a   Carbone, Kathryn ^a   Hsu, Henry ^a   Yolken, Robert ^b   Rubin, Steven ^a,c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUMPS VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; DILUTION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNITY; IMMUNOASSAY; INTERMETHOD COMPARISON; MEASLES; MUMPS VIRUS; PLAQUE REDUCTION NEUTRALIZATION ASSAY; PRIORITY JOURNAL; RUBELLA; SENSITIVITY AND SPECIFICITY; SEROLOGY; VIRUS NEUTRALIZATION; VIRUS PLAQUE;

ADOLESCENT; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; FEMALE; HUMANS; IMMUNITY, NATURAL; IMMUNOENZYME TECHNIQUES; MUMPS; MUMPS VACCINE; MUMPS VIRUS; NEUTRALIZATION TESTS; PLAQUE ASSAY; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

MUMPS VIRUS;

EID: 24744462931     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.9.4847-4851.2005     Document Type: Article

References (33)

1. Bottiger, M., B. Christenson, J. Taranger, and M. Bergman. 1985. Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of schoolchildren. Vaccine 3:113-116.
2. Briss, P. A., L. J. Fehrs, R. A. Parker, P. F. Wright, E. C. Sannella, R. H. Hutcheson, and W. Schaffner. 1994. Sustained transmission of mumps in a highly vaccinated population-assessment of primary vaccine failure and waning vaccine-induced immunity. J. Infect. Dis. 169:77-82.
3. Buynak, E. B., J. E. Whitman, Jr., R. R. Roehm, D. H. Morton, G. P. Lampson, and M. R. Hilleman. 1967. Comparison of neutralization and hemagglutination-inhibition techniques for measuring mumps antibody. Proc. Soc. Exp. Biol. Med. 125:1068-1071.
4. Christenson, B., and M. Bottiger. 1990. Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus. Biologicals 18:213-219.
5. Crowley, B., and M. A. Afzal. 2002. Mumps virus reinfection-clinical findings and serological vagaries. Commun. Dis. Public Health 5:311-313.
6. Fedova, D., M. Bruckova, V. Plesnik, D. Slonim, J. Sejda, E. Svandova, and I. Kubinova. 1987. Detection of postvaccination mumps virus antibody by neutralization test, enzyme-linked immunosorbent assay and sensitive hemagglutination inhibition test. J. Hyg. Epidemiol. Microbiol. Immunol. 31:409-422.
7. Grose, C., B. J. Edmond, and P. A. Brunell. 1979. Complement-enhanced neutralizing antibody response to varicella-zoster virus. J. Infect. Dis. 139:432-437.
8. Harmsen, T., M. Jongerius, C. van der Zwan, A. Plantinga, C. Kraaijeveld, and G. Berbers. 1992. Comparison of a neutralization enzyme immunoassay and an ELISA for evaluation of immune status of children vaccinated for mumps. J. Virol. Methods 30:2139-2144.
9. Hersh, B. S., P. E. Fine, W. K. Kent, S. L. Cochi, L. H. Kahn, E. R. Zell, P. L. Hays, and C. L. Wood. 1991. Mumps outbreak in a highly vaccinated population. J. Pediatr. 119:187-193.
10. Hilleman, M. R., R. E. Weibel, E. B. Buynak, J. Stokes, Jr., and J. E. Whitman, Jr. 1967. Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. N. Engl. J. Med. 276:252-258.
11. Leinikki, P. O., I. Shekarchi, N. Tzan, D. L. Madden, and J. L. Sever. 1979. Evaluation of enzyme-linked immunosorbent assay (ELISA) for mumps virus antibodies. Proc. Soc. Exp. Biol. Med. 160:363-367.
12. Linde, G. A., M. Granstrom, and C. Orvell. 1987. Immunoglobulin class and immunoglobulin G subclass enzyme-linked immunosorbent assays compared with microneutralization assay for serodiagnosis of mumps infection and determination of immunity. J. Clin. Microbiol. 25:1653-1658.
13. Nigro, G., F. Nanni, and M. Midulla. 1986. Determination of vaccine-induced and naturally acquired class-specific mumps antibodies by two indirect enzyme-linked immunosorbent assays. J. Virol. Methods 13:91-106.
14. Orvell, C. 1978. Immunological properties of purified mumps virus glycoproteins. J. Gen. Virol. 41:517-526.
15. Orvell, C. 1984. The reactions of monoclonal antibodies with structural proteins of mumps virus. J. Immunol. 132:2622-2629.
16. Pipkin, P. A., M. A. Afzal, A. B. Heath, and P. D. Minor. 1999. Assay of humoral immunity to mumps virus. J. Virol. Methods 79:219-225.
17. Poltera, A. A., and C. Herzog. 2000. Vaccine-induced antibodies by commercial test kits, the case of the Rubini mumps and the Edmonston-Zagreb measles vaccine strains. Vaccine 19:396-398.
18. Pons, C., T. Pelayo, I. Pachon, A. Galmes, L. Gonzalez, C. Sanchez, and F. Martinez. 2000. Two outbreaks of mumps in children vaccinated with the Rubini strain in Spain indicate low vaccine efficacy. Euro. Surveill. 5:80-84.
19. Ratnam, S., V. Gadag, R. West, J. Burris, E. Oates, F. Stead, and N. Bouilianne. 1995. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J. Clin. Microbiol. 33:811-815.
20. Schlegel, M., J. J. Osterwalder, R. L. Galeazzi, and P. L. Vernazza. 1999. Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ 319:352.
21. Schlegel, M., and P. L. Vernazza. 1998. Immune response and vaccine efficiency. Vaccine 16:1256.
22. Schwarzer, S., S. Reibel, A. B. Lang, M. M. Struck, B. Finkel, E. Gerike, A. Tischer, M. Gassner, R. Gluck, B. Stuck, and S. J. Cryz, Jr. 1998. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine 16:298-304.
23. Server, A. C., D. C. Merz, M. N. Waxham, and J. S. Wolinsky. 1982. Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein. Infect. Immun. 35:179-186.
24. Shehab, Z. M., P. A. Brunell, and E. Cobb. 1984. Epidemiological standardization of a test for susceptibility to mumps. J. Infect. Dis. 149:810-812.
25. Strohle, A., K. Eggenberger, C. A. Steiner, L. Matter, and D. Germann. 1997. Studien zur Mumps-Epidemie bei geimpften Kindern in der Westschweiz. Schweiz. Med. Wochenschr. 127:1124-1133.
26. Sullivan, K. M., T. J. Halpin, J. S. Marks, and R. Kim-Farley. 1985. Effectiveness of mumps vaccine in a school outbreak. Am. J. Dis. Child. 139:909-912.
27. Takayama, M., and A. Oya. 1981. A single serum dilution method for the quantitation of neutralizing antibodies to varicella-zoster virus. Biken J. 24:109-118.
28. Tsuji, M., K. Sasaki, M. Nakagawa, T. Mori, T. Nakayama, S. Makino, and M. Okamura. 1983. Improved enzyme-linked immunosorbent assay (ELISA) for the detection of mumps virus antibodies. Kitasato Arch. Exp. Med. 56:137-147.
29. Weibel, R. E., E. B. Buynak, A. A. McLean, and M. R. Hilleman. 1975. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics 56:380-387.
30. Weibel, R. E., E. B. Buynak, J. Stokes, Jr., and M. R. Hilleman. 1970. Persistence of immunity four years following Jeryl Lynn strain live mumps virus vaccine. Pediatrics 45:821-826.
31. Weibel, R. E., E. B. Buynak, J. E. Whitman, Jr., M. B. Leagus, J. Stokes, Jr., and M. R. Hilleman. 1969. Jeryl Lynn strain live mumps virus vaccine. Durable immunity for three years following vaccination. JAMA 207:1667-1670.
32. Weibel, R. E., J. Stokes, Jr., E. B. Buynak, J. E. Whitman, Jr., and M. R. Hilleman. 1967. Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation. N. Engl. J. Med. 276:245-251.
33. Wharton, M., S. L. Cochi, R. H. Hutcheson, J. M. Bistowish, and W. Schaffner. 1988. A large outbreak of mumps in the postvaccine era. J. Infect. Dis. 158:1253-1260.